Prostate Cancer Foundation

The pcf research enterprise is a peer-review research funding program that provides funding to 3250 scientists conducting innovative research projects at more than 250 leading Cancer centers and universities. Priority is given to high-risk, high-return projects with the greatest potential to improve survival and the overall quality of life for men with Prostate Cancer. The cornerstone of the pcf research enterprise in 2022 was our challenge awards program and new tactical awards program. Pcf challenge and tactical awards support cross-disciplinary teams of investigators conducting pioneering research to address critical unmet medical needs for Prostate Cancer patients. In 2022, pcf funded 19 multi-year team research projects that each offer high potential for improved detection, enhanced quality of life and higher survival rates. All pcf-funded researchers are required to openly share their unpublished findings on an annual basis with the entire global research community of pcf award recipients.

More than 12,000 men cared for by the department of veterans affairs (va) hospitals are newly diagnosed with Prostate Cancer each year, making it the most frequently diagnosed Cancer among veterans. The pcf-va partnership is expanding research into Prostate Cancer precision oncology treatment options. The collaboration is expanding the number of precision oncology clinical studies conducted at veterans healthadministration hospitals, ensuring that eligible veterans can access and participate in these studies. In 2022, pcf's dedicated network of centers of excellence (coe) executed the ambitious mission of improving the care for thousands of u.s. veterans with Prostate Cancer. These centers are located in portland, or, san francisco, ca, philadelphia, pa, Washington, dc, durham, nc, tampa bay, fl, seattle, wa, chicago, il, bronx, ny, los angeles, ca, manhattan, ny, ann arbor, mi, atlanta, ga, and baltimore, md. Pcf's veterans health initiative was founded in 2016 as part of the Cancer moonshot to ensure veterans, who deserve the very best from our country, receive the very best research and precision oncology care for Prostate Cancer available through the pcf-va network.

Pcf created the young investigator award program with one goal: to build a gifted cohort of human capital supporting the next generation of Prostate Cancer researchers. Awards are made to early-career scientists working in a research environment capable of supporting high-impact Prostate Cancer research, drawn from a variety of medical research disciplines. The award funds may be used flexibly to advance the career and research efforts of the awardee. Mentorship is required for every pcf young investigator. Since 2007, pcf has awarded more than $65 million to advance the early careers of 383 pcf young investigators, ensuring a continued stream of human capital into our research community. Many have become major research program leaders. The pcf young investigator program plays an integral role in championing, mentoring, and identifying strong leadership potential in early-career human capital investments.

For more than 3 million american men and their families fighting Prostate Cancer and millions more globally, pcf is a primary source for new standard-of-care and research information. Pcf educates the public about Prostate Cancer risks, screening, prevention, treatment options, and side effects. We connect patients, loved ones, care providers and scientists to critical updates, the latest developments, best practices, and news from the treatment pipeline. Since pcf's inception, and through its efforts, patients around the world are living longer, suffering fewer complications, and enjoying better quality of life. Pcf is committed to creating a global public square for Prostate Cancer, in service to our mission of ending death and suffering from the disease. Through year-round awareness and education programs, pcf aims to spur men and women alike to talk about this disease, to understand its urgency, and to have information-driven hope.